Brief: Rocket Pharmaceuticals Presents Positive Data From LV Hematology Portfolio At The 27th Annual Meeting Of The American Society Of Gene And Cell Therapy
10/05/2024 11:35
May 10 (Reuters) - Rocket Pharmaceuticals Inc RCKT.O :
* ROCKET PHARMACEUTICALS PRESENTS POSITIVE DATA FROM LV
HEMATOLOGY
PORTFOLIO AT THE 27TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF
GENE AND CELL THERAPY (ASGCT)
* ROCKET PHARMACEUTICALS INC - WELL-TOLERATED SAFETY PROFILE
IN
PKD PATIENTS UP TO 36 MONTHS AFTER RP-L301 TREATMENT
Source text for Eikon: ID:nBw1G38Na
Further company coverage: RCKT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rocket Pharmaceuticals
See all newsRocket Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Rocket Pharmaceuticals, Inc. expected to post a loss of 42 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Accendra Health, Celestica, Sionna Therapeutics
Rocket Pharmaceuticals posts Q2 profit helped by PRV sale
Brief: Rocket Pharmaceuticals Q2 EPS USD 1.08